

Novel Biological and Pharmacological Interventions for Obesity Prevention

Novo Nordisk established the **Transformational Prevention Unit (TPU)** to develop **scientifically valid** and **commercially scalable** solutions to **predict and pre-empt the risk of obesity and its consequences**, so people can live healthier and longer lives. The TPU is committed to **building novel, multi-sector partnerships** that combine scientific, technological and implementation expertise across four inter-related product categories to deliver impactful solutions.



To achieve this, the TPU team at Novo Nordisk is seeking science data-backed opportunities to advance the **Biological Intervention** product category:

Approaches of Interest:

- All approaches entailing substances that have a biological effect on weight management and promoting metabolic health are of interest, including, **pharmaceutical compounds, microbiome modulators, and nutraceuticals**. Expanding on, or repurposing of, assets capable of weight reduction for preventative approaches, is also in scope
- Solutions for prevention of obesity related cardiometabolic disorders (e.g. type 2 diabetes, CVD, MASH, CKD), preferably in combination with effects on weight management
- Open to **all modalities**, including medical devices used in the delivery of a therapeutic compound
- **All delivery routes** will be considered, with higher priority given to orally delivered solutions
- All mechanisms of action are of interest, including **affecting appetite, energy expenditure, and novel MoAs**

Out of Scope:

- Behavioral approaches to weight management
- Medical devices used only to monitor weight and cardiometabolic health

Developmental Stages of Interest:

- Opportunities from preclinical research onwards are in scope. Research with clinical validation will be given priority
- There is a strong preference for preclinical research to have *in vivo* validation
- The ability to demonstrate safety of proposed intervention will be an advantage

Submission Information

Submission of one-page, 200–300-word briefs is encouraged, along with any optional supplementary information e.g. relevant publications. In submitting to this campaign, you confirm that your submission contains only non-confidential information.

Opportunity for Collaboration

Our client is open to a range of collaboration opportunities, with the most appropriate outcome being decided on a case-by-case basis. Example outcomes include licensing assets, co-development, and research collaborations.

Opportunities sought

-  Technologies
-  Academics and expertise
-  Centres of excellence
-  Research projects
-  Spinout companies
-  Biotech assets

Submissions

Please submit relevant, non-confidential opportunities online [here](#)

Deadline: **10th March 2025 - 11:59 pm GMT**

Have any questions?

Contact our team at discover@in-part.co.uk